Josamycin

Summary

Josamycin (CHEMBL224436) is a phase-3 clinical-stage small-molecule antibacterial drug (ATC J01FA07); indicated across 2 conditions including bacterial infectious disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: J01FA07
• Indications: 2 conditions
• Clinical trials: 1
• Chemistry: 828 Da · C42H69NO15

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL224436
Name	Josamycin
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	5282165
ChEBI	CHEBI:31739
ATC	J01FA07
Molecular formula	C42H69NO15
Molecular weight	828
InChIKey	XJSFLOJWULLJQS-NGVXBBESSA-N

SMILES: C[C@@H]1C/C=C/C=C/[C@@H]([C@@H](C[C@@H]([C@@H]([C@H]([C@@H](CC(=O)O1)OC(=O)C)OC)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C)O[C@H]3C[C@@]([C@H]([C@@H](O3)C)OC(=O)CC(C)C)(C)O)N(C)C)O)CC=O)C)O

IUPAC name: [(2S,3S,4R,6S)-6-[(2R,3S,4R,5R,6S)-6-[[(4R,5S,6S,7R,9R,10R,11E,13E,16R)-4-acetyloxy-10-hydroxy-5-methoxy-9,16-dimethyl-2-oxo-7-(2-oxoethyl)-1-oxacyclohexadeca-11,13-dien-6-yl]oxy]-4-(dimethylamino)-5-hydroxy-2-methyloxan-3-yl]oxy-4-hydroxy-2,4-dimethyloxan-3-yl] 3-methylbutanoate

ChEBI definition: A macrolide antibiotic produced by certain strains of Streptomyces narbonensis var. josamyceticus.

Pharmacological roles (ChEBI): antibacterial drug.

Other ChEBI roles (chemical / environmental): metabolite.

Also known as: EN-141, Iosalide, Jomybel, Josamicina, Josamina, Josamycin, Josamycin propionate, Josamycine, Kitasamycin a3, Leucomycin a3, Turimycin a5, josamycin

Patent coverage: 2,526 distinct patent families (9,073 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Bacterial 70S ribosome.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P02358	5.92	IC50	1200	nM	CHEMBL_ACT_14611103

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
bacterial infectious disease	3	MONDO:0005113	EFO:0000771

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00718705	PHASE3	COMPLETED	Reduction of Spontaneous Prematurity by Antibiotic Treatment (Josamycin)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).